Clinical trial

Calcium Aspirin Multiple Micronutrients (CAMMS) or Iron-folic Acid (IFA) to Reduce Preterm Birth

Name
INV-036663
Description
This trial will evaluate the impact of an integrated intervention of daily maternal calcium, aspirin, and multiple micronutrients (CAMMS) compared to iron-folic acid (IFA) during pregnancy on preterm birth and other adverse birth outcomes. Both interventions will be delivered through existing antenatal service platforms using context-specific strategies informed by formative research incorporating human-centered design processes to achieve high acceptability and high adherence, in three low-income countries with diverse contexts: Burkina Faso, Pakistan, and Zimbabwe.
Trial arms
Trial start
2024-04-01
Estimated PCD
2026-06-30
Trial end
2026-12-31
Status
Withdrawn
Phase
Early phase I
Treatment
Calcium aspirin multiple micronutrients
Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
Arms:
Calcium aspirin multiple micronutrients
Other names:
CAMMS
Iron-folic Acid
Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
Arms:
Iron folic acid
Other names:
IFA
Primary endpoint
Total preterm birth
At birth
Eligibility criteria
Inclusion Criteria: * Woman, confirmed pregnant by urinary pregnancy test * 6\<20 weeks' gestation determined by fetal ultrasound exam; * Pregnancy must be intrauterine; multiple fetus pregnancies are eligible. * Women must be willing and able to give informed consent; * willing to receive antenatal visits at one of the study clinics. * In Burkina Faso, women must be willing to take monthly sulfadoxine-pyrimethamine. Exclusion Criteria: * Pregnant women who are currently taking aspirin, calcium, or MMS; * have a history of peptic ulcer or have any other contraindications to any of the study drugs; * have acute or chronic condition that might interfere with the study as judged by the research clinician including severe anemia defined as Hb\<5 g/dL; * have other reasons which, at the study research physician's discretion, mean that receipt of the study drugs or participation in the trial would not be advisable. NOTE: Women who have been started on IFA by MoH or private health care provider but are willing discontinue the IFA dispensed by MoH and to be randomized to IFA or CAMMS will not be excluded.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Pregnant women will be individually randomized to daily CAMMS or IFA from recruitment (at 6\\<20 weeks gestation) to delivery.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2024-04-23

1 organization

1 product

5 indications

Indication
Preterm Labour
Indication
Neonatal Death